Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis

Table 2 Ranking profiles in the bayesian network Meta-analysis

Pathological complete response		Major Pathological response		Event-free survival		Rates of undergoing surgery		R0 resection rate		Grade 3 or Higher AEs
Treatment	p Score	Treatment	p Score	Treatment	p Score	Treatment	p Score	Treatment	p Score	Treatment	p Score
Tori-CT	0.9608	Tori-CT	0.8298	Tori-CT	0.9214	Nivo-CT	0.7208	Pemb-CT	0.717	Tori-CT	0.9157
TIS-CT	0.7598	Camr-CT	0.7931	Camr-CT	0.6167	Tori-CT	0.681	Ipi + Nivo-CT	0.6099	Camr-CT	0.8634
Nivo-CT	0.6214	Ipi + Nivo-CT	0.7839	TIS-CT	0.5903	TIS-CT	0.6706	Camr-CT	0.6069	Nivo-CT	0.5304
Ipi + Nivo-CT	0.5858	TIS-CT	0.6665	Pemb-CT	0.5482	Pemb-CT	0.4961	Tori-CT	0.571	TIS-CT	0.524
Camr-CT	0.3796	Nivo-CT	0.4371	Nivo-CT	0.4921	Durv-CT	0.4309	Durv-CT	0.5465	Pemb-CT	0.3816
Pemb-CT	0.3788	Durv-CT	0.2496	Durv-CT	0.3178	Camr-CT	0.4265	Nivo-CT	0.3173	Durv-CT	0.3706
Durv-CT	0.3124	Pemb-CT	0.2399	CT	0.0135	CT	0.3599	CT	0.1315	CT	0.3631
CT	0.0014	CT	0.000			Ipi + Nivo-CT	0.2141			Ipi + Nivo-CT	0.0512

CT: chemotherapy; Nivo-CT: nivolumab plus chemotherapy, Tori-CT: Toripalimab plus chemotherapy; Durv-CT: duvalumab plus chemotherapy, Pemb-CT: pembrolizumab plus chemotherapy; Tis-CT: Tislelizumab plus chemotherapy; Ipi + Nivo-CT: ipilimumab plus nivolumab plus chemotherapy

ISSN: 1471-2466